Using ATP to improve depression symptoms
A Double-blind Randomized Controlled Trial of Adenosine Disodium Triphosphate in Improving Moderate to Severe Depressions
This study is testing if adding a substance called ATP to the depression medication escitalopram can help people with moderate to severe depression feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06266715 on ClinicalTrials.gov |
What this trial studies
This clinical study is a randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of adenosine disodium triphosphate (ATP) in conjunction with escitalopram for treating moderate to severe depression. A total of 120 participants will be recruited and randomly assigned to either the ATP group or a control group receiving a placebo. The study will assess changes in depression severity using the Hamilton Depression Scale (HAMD-24) and other cognitive and inflammatory markers over a 4-week intervention period. The aim is to determine if ATP can enhance the therapeutic effects of escitalopram in depressed patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-65 who meet the criteria for moderate to severe depression and have not used psychotropic medications recently.
Not a fit: Patients with major mental disorders other than depression, neurological disorders, or those at high risk of suicide may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new adjunctive treatment option for patients suffering from moderate to severe depression.
How similar studies have performed: While the use of ATP in depression treatment is not widely tested, similar studies exploring adjunctive therapies for depression have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meet the diagnostic and statistical manual of mental disorders-5 diagnostic criteria for moderate to severe depression. * HAMD-24 scores ≥ 20. * 18-65 female or male. * Participants who have not used any psychotropic medications within one month prior to study and never had a treatment with escitalopram. * Individuals without contraindications to selective serotonin reuptake inhibitor. * Individuals without contraindications to ATP. * Written informed consent. Exclusion Criteria: * Participants with various major mental disorders other than depression (bipolar disorder, any psychotic disorder, Personality Disorders, alcohol use disorder, substance use disorder, and disorders due to medical or organic cause) assessed using Chinese version of the Mini International Neuropsychiatric Interview (MINI). * Individuals with neurological disorders such as dementia. * Individuals with a high risk of suicide. * Pregnant and lactating women. * Contraindications to MRI. * Physician evaluation was not suitable for participants in this study.
Where this trial is running
Guangzhou, Guangdong
- Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Bin Zhang, PhD
- Email: zhang73bin@hotmail.com
- Phone: 86-020-62786731
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.